Intensity Therapeutics, Inc. (INTS) — SEC Filings
Intensity Therapeutics, Inc. (INTS) — 38 SEC filings. Latest: 8-K (Dec 5, 2025). Includes 23 8-K, 5 10-Q, 3 DEF 14A.
View Intensity Therapeutics, Inc. on SEC EDGAR
Overview
Intensity Therapeutics, Inc. (INTS) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 4, 2025: Intensity Therapeutics, Inc. filed an 8-K on December 4, 2025, reporting on 'Other Events' and 'Financial Statements and Exhibits'. The filing does not contain specific financial figures or event details beyond the reporting of these categories.
Sentiment Summary
Across 38 filings, the sentiment breakdown is: 4 bearish, 32 neutral, 2 mixed. The dominant filing sentiment for Intensity Therapeutics, Inc. is neutral.
Filing Type Overview
Intensity Therapeutics, Inc. (INTS) has filed 23 8-K, 5 10-Q, 3 DEF 14A, 1 S-1/A, 2 S-1, 2 10-K, 2 SC 13G with the SEC between Feb 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (38)
Risk Profile
Risk Assessment: Of INTS's 32 recent filings, 6 were flagged as high-risk, 14 as medium-risk, and 12 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$2.671M |
| EPS | -$0.06 |
| Debt-to-Equity | 0.33 |
| Cash Position | $7.067M |
| Operating Margin | N/A |
| Total Assets | $9.585M |
| Total Debt | $2.363M |
Key Executives
- Lewis H. Bender
- Joseph Talamo
- Jeffrey P. Schultz, Esq.
- Ivan K. Blumenthal, Es
- Dr. Robert L. Ferris
- Dr. Jonathan M. Roth
- Dr. David M. Epstein
- Dr. James M. Musser
Industry Context
Intensity Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing novel cancer therapies. The industry is characterized by long development cycles, high failure rates, and significant regulatory hurdles. Success often depends on groundbreaking scientific innovation, successful clinical trial execution, and substantial funding to navigate these challenges.
Top Tags
Biotechnology (6) · biotech (6) · corporate-governance (4) · regulatory-filing (4) · sec-filing (3) · 8-k (3) · shareholder-vote (3) · delisting (3) · material-definitive-agreement (3) · 10-Q (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Cash and cash equivalents | $7.067M | Increased from $2.590M at December 31, 2024 |
| Net loss for nine months ended Sept 30, 2025 | $8.555M | Reduced from $13.087M in prior year |
| Net loss for three months ended Sept 30, 2025 | $2.671M | Reduced from $3.513M in prior year |
| Research and development expenses for nine months ended Sept 30, 2025 | $5.283M | Decreased from $8.529M in prior year |
| Research and development expenses for three months ended Sept 30, 2025 | $1.553M | Decreased from $2.151M in prior year |
| Net cash provided by financing activities | $11.309M | Significant increase from $424K in prior year |
| Shares of common stock outstanding | 60,064,965 | As of November 5, 2025 |
| Accumulated deficit | $75.3M | As of September 30, 2025 |
| Shares Outstanding | 49,055,462 | Number of common stock shares entitled to vote as of August 29, 2025 record date |
| Reverse Stock Split Ratio Range | 1:5 to 1:30 | Proposed range for the reverse stock split, exact ratio to be set by the board |
| Special Meeting Date | October 22, 2025 | Date stockholders will vote on the reverse stock split proposal |
| Record Date | August 29, 2025 | Date for determining stockholders eligible to vote at the Special Meeting |
| Quorum Requirement | 16,351,821 | Minimum number of shares needed to be present or represented for a valid meeting |
| Revenue | $0 | No revenue reported for Q2 2025 or YTD 2025, consistent with pre-commercial stage. |
| Net Loss (Q2 2025) | $5.5M | Decreased from $6.2M in Q2 2024, indicating slightly improved cost management or timing of expenses. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Intensity Therapeutics, Inc. (INTS)?
Intensity Therapeutics, Inc. has 38 recent SEC filings from Feb 2024 to Dec 2025, including 23 8-K, 5 10-Q, 3 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of INTS filings?
Across 38 filings, the sentiment breakdown is: 4 bearish, 32 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Intensity Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Intensity Therapeutics, Inc. (INTS) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Intensity Therapeutics, Inc.?
Key financial highlights from Intensity Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for INTS?
The investment thesis for INTS includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Intensity Therapeutics, Inc.?
Key executives identified across Intensity Therapeutics, Inc.'s filings include Lewis H. Bender, Joseph Talamo, Jeffrey P. Schultz, Esq., Ivan K. Blumenthal, Es, Dr. Robert L. Ferris and 3 others.
What are the main risk factors for Intensity Therapeutics, Inc. stock?
Of INTS's 32 assessed filings, 6 were flagged high-risk, 14 medium-risk, and 12 low-risk.
What are recent predictions and forward guidance from Intensity Therapeutics, Inc.?
Forward guidance and predictions for Intensity Therapeutics, Inc. are extracted from SEC filings as they are enriched.